SCHEMBL1750940

SCHEMBL1750940

c1cncc(-c2ncc3c(n2)NCN3)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 4/20 0.49
ALDH1A1 P00352 4/20 0.46
LMNA P02545 3/20 0.46
HSD17B10 Q99714 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
ALOX15 P16050 2/20 0.46
KDM4E B2RXH2 1/20 0.46
TP53 P04637 1/20 0.46
MAPT P10636 1/20 0.46
HPGD P15428 1/20 0.46
HTT P42858 1/20 0.46
HPGDS O60760 1/20 0.43
POLB P06746 1/20 0.43
CYP3A4 P08684 7/20 0.42
CYP1A2 P05177 7/20 0.42
CYP2D6 P10635 5/20 0.42
CLK4 Q9HAZ1 3/20 0.42
TSHR P16473 1/20 0.42
CHRNB2 P17787 1/20 0.41
CHRNA5 P30532 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1750073 0.85 NPC1 (0.42) ALDH1A1LMNASMN1; SMN2MAPTHPGDS
SCHEMBL17811701 0.71 CYP11B1 (0.52) CYP2A6ALDH1A1LMNAHSD17B10SMN1; SMN2
SCHEMBL8016565 0.70 CYP2A6 (0.65) CYP2A6ALDH1A1LMNAHSD17B10SMN1; SMN2
SCHEMBL5032444 0.69 SMN1; SMN2 (0.73) CYP2A6ALDH1A1LMNAHSD17B10SMN1; SMN2
SCHEMBL29543568 0.69 SMN1; SMN2 (0.73) CYP2A6ALDH1A1LMNAHSD17B10SMN1; SMN2
SCHEMBL16886043 0.68 CYP2A6 (0.75) CYP2A6ALDH1A1LMNAHSD17B10SMN1; SMN2
SCHEMBL2100709 0.67 CYP2A6 (1.00) CYP2A6ALDH1A1LMNAHSD17B10SMN1; SMN2
SCHEMBL4119429 0.67 CYP2A6 (0.60) CYP2A6ALDH1A1LMNAHSD17B10SMN1; SMN2
SCHEMBL29859251 0.67 LMNA (0.61) CYP2A6ALDH1A1LMNAHSD17B10SMN1; SMN2
SCHEMBL14983678 0.67 CYP2A6 (0.55) CYP2A6ALDH1A1LMNAHSD17B10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110224217-A1 METHODS OF TREATMENT USING HETEROARYL COMPOUNDS AND COMPOSITIONS THEREOF SIGNAL PHARMACEUTICALS, LLC 2011-09-15 US claimed
US-20090042890-A1 Heteroaryl compounds, compositions thereof, and methods of treatment therewith SIGNAL PHARMACEUTICALS, LLC 2009-02-12 US claimed
US-20110224217-A1 METHODS OF TREATMENT USING HETEROARYL COMPOUNDS AND COMPOSITIONS THEREOF SIGNAL PHARMACEUTICALS, LLC 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224217-A1 METHODS OF TREATMENT USING HETEROARYL COMPOUNDS AND COMPOSITIONS THEREOF JAK2, CHEK2, PHKG1 CYP2A6 1657/4885ALDH1A1 2430/4885LMNA 1628/4885
US-20090042890-A1 Heteroaryl compounds, compositions thereof, and methods of treatment therewith JAK2, CHEK2, SRC CYP2A6 1331/4885ALDH1A1 2113/4885LMNA 1596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.